

## *Special announcements*

# Editorship of *Annals of the Rheumatic Diseases*

The present editor is due to retire from this post in 1988. Anyone who may be interested in being considered for appointment as editor is invited to seek further information in confidence from Professor Harry Currey. It is intended that plans for the future editorial structure and management shall be left open for discussion with the new appointee.

## Rapid Reports

A rapid publication facility for authors, Rapid Reports, is to be introduced later this year. Papers that can be accommodated in two pages of the journal, e.g., 800 words + 10 references + a small figure or table, will be treated as Rapid Reports. They will be given priority treatment and it will be aimed to publish them within three months of acceptance. The papers should report completed work, not merely preliminary investigations, and should follow the style of full length papers. Authors will not see proofs but will be consulted about major amendments. Proofs will be checked in the editorial office. Original artwork should be provided.

## 4th Mediterranean Congress of Rheumatology

(under the patronage of EULAR)  
and

## 1st Mediterranean Symposium on Behçet's Disease

The Congress and the Symposium will be held in Istanbul, Turkey on 2-3 June and 4 June 1988 respectively.

The main topics of the Congress are: juvenile chronic arthritis, familial Mediterranean fever, amyloidosis associated with rheumatic diseases.

The topic of the Symposium is vasculitis in Behçet's disease.

Enquiries to Prof. N. Dilşen, Istanbul Faculty of Medicine, Division of Rheumatology, Çapa, Topkapi, Istanbul, Turkey.

## ABC OF COMPUTING

A J ASBURY

Although computers are being widely used in medicine, their possibilities and limitations are still not clear to many potential users. This book, aimed at the non-expert, describes some of the uses of computers in medicine; because most doctors' involvement will be indirect, liaising with computer experts rather than designing systems themselves, the book concentrates on concepts rather than detailed descriptions of how computers work. It provides a useful introduction for the doctor who wants to know how computers can contribute to his practice of medicine.

Price: Inland £6.50; Overseas £8.00\*/USA \$14.00\*  
(Inland £6.00; Overseas £7.50\*/USA \$13.00\*  
to BMA members)

\*including air mail postage

Payment must be enclosed with order

Order your copy now

From: The Publisher, British Medical Journal  
PO Box 295  
London WC1H 9TE  
or any leading bookseller

# Plaquenil

hydroxychloroquine

## PRESCRIBING INFORMATION

An antimalarial used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight.

Each tablet contains 200mg hydroxychloroquine sulphate BP.

Supplied in bottles of 100 tablets. Basic NHS cost £29.93. PL 0071/5083.

**Adult dose** *Initially:* 400mg daily in divided doses  
*Maintenance:* 200-400mg daily

Dose should not exceed 6.5mg/kg/day.

**Children** See Data-Sheet for details.

**Contra-indications** Pregnancy, maculopathy.

**Caution** In patients with renal and hepatic impairment, porphyria, psoriasis, severe neurological, gastro-intestinal or blood disorders, G-6-PD deficiency, or hypersensitivity to quinine. Also the concomitant use of drugs which may cause adverse ocular or skin reactions. All patients must have an ophthalmological examination before treatment starts and at least every 6 months during treatment. Plaquenil should be discontinued immediately in any patient who develops a pigmentary abnormality or visual field defect. Disturbance of visual accommodation may occur on first taking Plaquenil and patients should be warned regarding driving or operating machinery.

**Side effects** Retinal changes can occur but appear to be uncommon if the recommended daily dose is not exceeded. Reversible corneal opacities have been reported. Other side-effects include gastro-intestinal disturbances, skin reactions, depigmentation or (rarely) loss of hair; less frequently, muscle weakness, vertigo, tinnitus, nerve deafness, headache, nervousness, emotional upsets and (rarely) bone marrow depression, neuromyotoxicity, and toxic psychosis.

Plaquenil is a registered trade mark.

1. Clin. Rheum. Dis. 1980; 6:545-66.
2. Am. J. Med. 1983; 18, July: 1-4.
3. Br. J. Clin. Pract. 1987 (Suppl 52); 41/10:24-27.
4. Br. J. Clin. Pract. 1987 (Suppl 52); 41/10:15-23.
5. Am. J. Med. 1983; 75, August: 321-325.
6. Clin. Rheumatol. 1984; 3(Suppl 1): 57-66.
7. Arthritis Rheum. 1984; 27(3): 267-276.
8. J Rheumatol. 1980; 7:825-830.
9. Br. J. Clin. Pract. 1987; (Suppl 52) 41/10:42-45.



Further information available from:

Sterling Research Laboratories, Onslow Street,  
Guildford, Surrey GU1 4YS.

(SRL1042)108